Phencyclidine hydrochloride

Pricing Availability   Qty
Description: Non-competitive NMDA antagonist
Alternative Names: PCP
Chemical Name: 1-(1-Phenylcyclohexyl)piperidine hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for Phencyclidine hydrochloride

Phencyclidine hydrochloride is a non-competitive NMDA receptor antagonist and sigma receptor agonist. Psychostimulant; induces rotational behavior, head-weaving and cognitive dysfunction in rats.

Technical Data for Phencyclidine hydrochloride

M. Wt 279.85
Formula C17H25N.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 956-90-1
PubChem ID 13727
InChI Key BUAJNGPDPGKBGV-UHFFFAOYSA-N
Smiles N2(CCCCC2)C1(C3=CC=CC=C3)CCCCC1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Phencyclidine hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 11.19 40

Preparing Stock Solutions for Phencyclidine hydrochloride

The following data is based on the product molecular weight 279.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.4 mM 8.93 mL 44.67 mL 89.33 mL
2 mM 1.79 mL 8.93 mL 17.87 mL
4 mM 0.89 mL 4.47 mL 8.93 mL
20 mM 0.18 mL 0.89 mL 1.79 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Phencyclidine hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Phencyclidine hydrochloride

References are publications that support the biological activity of the product.

Linders et al (1993) Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrochloride: a new potent and selective electrophilic affinity ligand for the NMDA receptor-c J.Med.Chem. 36 2499 PMID: 8355251

Jin et al (1997) The involvement of σ receptors in the choice reaction performance deficits induced by phencyclidine. Eur.J.Pharmacol. 319 147 PMID: 9042584

Sharp (1997) Phencyclidine (PCP) acts at σ sites to induce c-fos gene expression. Brain Res. 758 51 PMID: 9203533


If you know of a relevant reference for Phencyclidine hydrochloride, please let us know.

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: Phencyclidine hydrochloride, Phencyclidine hydrochloride supplier, σ, sigma, receptor, agonists, Non-competitive, NMDA, antagonists, General, Receptors, Glutamate, N-Methyl-D-Aspartate, iGluR, Ionotropic, PCP, Sigma-Related, 2557, Tocris Bioscience

Citations for Phencyclidine hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Phencyclidine hydrochloride. Do you know of a great paper that uses Phencyclidine hydrochloride from Tocris? Please let us know.

Reviews for Phencyclidine hydrochloride

There are currently no reviews for this product. Be the first to review Phencyclidine hydrochloride and earn rewards!

Have you used Phencyclidine hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.